Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation
Recent scientific studies (e.g., PubMed 2025, BMJ 2024) indicate a significant association between Depo-Provera use and increased risk of meningiomas. The FDA updated its warnings in late 2025 to include meningioma risks, citing reports of brain tumors following long-term use. The causation theory involves hormonal stimulation of tumor growth, with progesterone sensitivity being a key biological mechanism.
5,830
Pending actions
5,916
Total actions filed
Active
Status
02/07/2025
Established
Filing deadline
The Plaintiff Proof of Use/Injury Questionnaire deadline is 120 days from the case filing or transfer date into the MDL. The latest Case Management Order No. 11 was issued on March 6, 2026, which likely includes specific procedural deadlines. Daubert hearings are scheduled for May 2026. The FDA's December 2025 label warning and the December 2026 bellwether trial are key milestones.
Who qualifies
Plaintiffs must have used Depo-Provera for at least two injections and received a diagnosis of meningioma. Specific duration or dosage thresholds are not publicly specified and may be case-dependent.
Products involved
- Depo-Provera (Depot Medroxyprogesterone Acetate)
Alleged injuries
- meningiomas
- brain tumors
Bellwether trials
The first bellwether trial is scheduled for December 2026. As of March 2026, no recent verdicts from the MDL have been reported.
Settlement landscape
Settlement estimates range from approximately $75,000 to over $1,000,000 per case, with average settlements estimated over $100,000 and some exceeding $500,000. Past verdicts in similar cases have shown payouts averaging over $800,000, with jury verdicts exceeding $3 million.
Lead counsel
- Christopher A. Seeger (Seeger Weiss LLP)
- Bryan F. Aylstock (Aylstock, Witkin, Kreis & Overholtz PLLC)
- Ellen Relkin
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
